STOK Company Profile and Key Details

Q: Who are the executives of STOK?

Ms. Shamim RuffChief Regulatory OfficerDr. Edward M. Kaye M.D., Ph.D.Chief Executive Officer & DirectorMs. Dawn KalmarChief Communications OfficerMs. Joan WoodChief HR OfficerDr. Adrian R. Krainer Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory BoardMr. Stephen J. Tulipano CPA, CPA, MBAChief Financial OfficerMs. Isabel Aznarez Ph.D.Co-Founder & Group Vice President of Discovery ResearchDr. Huw M. Nash Ph.D.Chief Operating Officer & Chief Bus. OfficerMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D.Corporation Sec. & Gen. Counsel

NASDAQ : STOK

Stoke Therapeutics

$32.40

1.92+6.30%

At Close 4:00 PM

59.42

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Stoke Therapeutics, Inc. (STOK) stock surged +6.30%, trading at $32.40 on NASDAQ, up from the previous close of $30.48. The stock opened at $31.70, fluctuating between $31.06 and $33.48 in the recent session.

Stock Snapshot

30.48

Prev. Close

1.85B

Market Cap

31.06

Day Low

47.65

P/E Ratio

0.68

EPS (TTM)

-1.84

Cash Flow per Share

31.7

Open

57.12M

Number of Shares

33.48

Day High

84%

Free Float in %

3.55

Book Value

780.93K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	31.70	33.48	31.06	32.40	791.96K
Feb 05, 2026	32.43	34.01	30.33	30.48	712.87K
Feb 04, 2026	34.11	34.47	30.67	32.00	629.51K
Feb 03, 2026	31.02	33.83	31.01	33.79	503.64K
Feb 02, 2026	30.00	31.49	29.35	30.77	549.11K
Jan 30, 2026	30.56	31.08	29.96	30.34	539.4K
Jan 29, 2026	29.40	31.76	29.29	31.07	534.88K
Jan 28, 2026	29.67	30.14	29.14	29.40	526.34K
Jan 27, 2026	29.25	30.25	29.07	29.51	328.22K
Jan 26, 2026	29.04	29.99	28.81	29.25	454.24K
Jan 23, 2026	29.67	30.29	28.75	29.46	503.6K
Jan 22, 2026	29.61	30.96	29.58	30.05	689.74K
Jan 21, 2026	28.61	30.12	28.45	29.50	558.33K
Jan 20, 2026	28.00	28.89	27.01	28.72	886.71K
Jan 16, 2026	29.42	30.13	28.52	28.70	1.12M
Jan 15, 2026	31.17	31.70	29.23	29.28	779.7K
Jan 14, 2026	30.49	31.14	30.08	30.97	507.95K
Jan 13, 2026	29.01	30.63	28.27	30.58	631.24K
Jan 12, 2026	27.40	29.49	25.21	29.42	1.96M
Jan 09, 2026	33.91	34.34	32.46	32.85	617.32K

Contact Details

Bedford, MA 01730

United States

https://www.stoketherapeutics.com 781 430 8200

About Company

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stock Peers

ARGX

-8.86-1.08%

argenx SE$811.45 REGN

18.88+2.46%

Regeneron Pharmaceuticals, Inc.$785.51 UTHR

6.43+1.34%

United Therapeutics Corporation$485.36 VRTX

19.11+4.17%

Vertex Pharmaceuticals Incorporated$477.92 MDGL

14.18+3.06%

Madrigal Pharmaceuticals, Inc.$477.60 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-3.08-0.93%

Alnylam Pharmaceuticals, Inc.$328.16 PRAX

13.95+4.56%

Praxis Precision Medicines, Inc.$319.57 KRYS

5.1+1.91%

Krystal Biotech, Inc.$272.74 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Stoke Therapeutics, Inc. (NASDAQ:STOK) closed at $32.40 USD, gaining $1.92 (6.30%) from the previous close of $30.48. The stock is currently mid-range between its 52-week high and low $5.35 and $38.69. With a market capitalization of about $1.85 billion, Stoke Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 854.19 thousand shares, in line with its 52-week average. Headquartered in Bedford, MA, Stoke Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ian F. Smith, the company employs approximately 128 people and listed since June 19, 2019. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 6.48%, SMA50 3.03%, SMA200 51.4%). The stock’s 14-day RSI is 54.76 (neutral), while the ATR of 2.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -16.26% below its high and over 505.61% above its low. Average 10-day trading volume of 568.44 thousand shares is below the 3-month average of 828.04 thousand, indicating normal recent market interest.

Valuation Metrics

Stoke Therapeutics, Inc. trades at a P/E ratio of 46.61, slightly above the S&P 500 average, with a price-to-sales ratio of 8.96 and a price-to-book ratio of 6.14 trading at moderately above to book value. The P/FCF stands at 35.19, also above market averages.

Dividend & Fair Value

Stoke Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.36. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Stoke Therapeutics, Inc. generated EPS of $0.66 over the past year. Five-year average earnings growth is 1.74%. Wall Street analysts project EPS growth of -15.63% annually over the next five years. The latest quarter delivered EPS of -$0.65. The next quarter is forecast at -$0.72. Next year's EPS is expected at $3.84. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 18 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $22.00. The high target offers 54.32% upside. The low target suggests -32.1% downside. The mean target is $31.64. This offers -2.35% upside. Stoke Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by 14.04%. The prior quarter beat by -29.82%. Over the last six quarters, Apple has recorded several small beats. These include -19.3% in August 07, 2024.

Shareholding & Insider Activity

Stoke Therapeutics, Inc. has 54.80 million shares outstanding. The public float is 38.11 million shares, elevated short interest at 24.69% of float. This equals 11.19 million shares. The short ratio is 12.26 days. Institutional investors hold 132.87% of the float. Insiders own 9.62%. Apple Tree Partners IV, L.P. holds 17.16 million shares, Harrison Seth Loring has 17.16 million shares and Skorpios Trust has 3.91 million shares. Over the past six months, insider transactions show net selling. They sold 279.78 thousand shares across 32 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Stoke Therapeutics generated $8.78M in revenue, or $0.20 per share. Gross margin was 46.14%, operating margin -1307.21%, and net profit margin -1192.47%. Returns are negative, with ROA at -45.85% and ROE at -65.62%.
On valuation metrics, Stoke Therapeutics trades at a P/E of 46.61, P/S of 8.96 and P/B of 6.14. The current ratio is 6.53 and quick ratio is 6.53. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2147.51 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 18.17.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Stoke Therapeutics posted revenue of $8.78M, down slightly from $12.41M in the prior quarter. Gross profit was $4.05M (margin 46.14%). Operating income was - $114.77M (margin -1307.2%). Net income was- $104.70M (EPS - $2.38).
The company ended the quarter with $201.39M in cash and short-term investments, a total debt of $6.84M, and net debt of - $184.61M. Total assets were $228.34M, with equity of $159.57M. Financials further reflected weakness, with operating cash flow of - $81.07M, free cash flow of - $82.68M, and capital expenditures of - $1.62M.

Price Forecast & Outlook

Our AI price prediction model suggests that Stoke Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.86%, with price expected at $30.50 by February 20, 2026, within a range of $28.59 to $32.46 3-Month Outlook: Projected fall of -6.17%, reaching $30.40 by May 06, 2026, with a range of $30.02 to $30.85. 1-Year Outlook: Projected gain of 12.56%, with price at $36.47 by February 05, 2027, within a range of $34.38 to $38.25.

Key Takeaways

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares are flat -9.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Stoke Therapeutics, Inc. trading at a premium to the broader market with a P/E of 46.61. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $31.64, suggesting -2.35% downside. Our AI forecast model points to short-term weakness (-5.86% over two weeks), a medium-term fall (-6.17% over three months), and a longer-term gain (12.56% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Stoke Therapeutics, Inc. (STOK) stock price?

Stoke Therapeutics, Inc. (NASDAQ: STOK) stock price is $32.40 in the last trading session. During the trading session, STOK stock reached the peak price of $33.48 while $31.06 was the lowest point it dropped to. The percentage change in STOK stock occurred in the recent session was 6.3% while the dollar amount for the price change in STOK stock was $1.92.

STOK's industry and sector of operation?

The NASDAQ listed STOK is part of Biotechnology industry that operates in the broader Healthcare sector. Stoke Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of STOK?

Ms. Shamim Ruff
Chief Regulatory Officer
Dr. Edward M. Kaye M.D., Ph.D.
Chief Executive Officer & Director
Ms. Dawn Kalmar
Chief Communications Officer
Ms. Joan Wood
Chief HR Officer
Dr. Adrian R. Krainer Ph.D.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Mr. Stephen J. Tulipano CPA, CPA, MBA
Chief Financial Officer
Ms. Isabel Aznarez Ph.D.
Co-Founder & Group Vice President of Discovery Research
Dr. Huw M. Nash Ph.D.
Chief Operating Officer & Chief Bus. Officer
Mr. Eric Rojas
Head of Investor Relations
Mr. Jonathan Allan J.D.
Corporation Sec. & Gen. Counsel

How STOK did perform over past 52-week?

STOK's closing price is 505.61% higher than its 52-week low of $5.35 where as its distance from 52-week high of $38.69 is -16.26%.

How many employees does STOK have?

Number of STOK employees currently stands at 128.

Link for STOK official website?

Official Website of STOK is: https://www.stoketherapeutics.com

How do I contact STOK?

STOK could be contacted at phone 781 430 8200 and can also be accessed through its website. STOK operates from 45 Wiggins Avenue, Bedford, MA 01730, United States.

How many shares of STOK are traded daily?

STOK stock volume for the day was 780.93K shares. The average number of STOK shares traded daily for last 3 months was 854.19K.

What is the market cap of STOK currently?

The market value of STOK currently stands at $1.85B with its latest stock price at $32.40 and 57.12M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	128
Beta	1.11
Sales or Revenue	$8.78M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

STOK Company Profile and Key Details

Stoke Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics